OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist
Michel A. Steiner, John Gatfield, Catherine Brisbare‐Roch, et al.
ChemMedChem (2013) Vol. 8, Iss. 6, pp. 898-903
Closed Access | Times Cited: 87
Michel A. Steiner, John Gatfield, Catherine Brisbare‐Roch, et al.
ChemMedChem (2013) Vol. 8, Iss. 6, pp. 898-903
Closed Access | Times Cited: 87
Showing 1-25 of 87 citing articles:
The role of orexin in motivated behaviours
Takeshi Sakurai
Nature reviews. Neuroscience (2014) Vol. 15, Iss. 11, pp. 719-731
Closed Access | Times Cited: 414
Takeshi Sakurai
Nature reviews. Neuroscience (2014) Vol. 15, Iss. 11, pp. 719-731
Closed Access | Times Cited: 414
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94
Pascal Bonaventure, Sujin Yun, Philip L. Johnson, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 352, Iss. 3, pp. 590-601
Open Access | Times Cited: 94
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
Jiann Wei Yeoh, Erin J. Campbell, Morgan H. James, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 86
Jiann Wei Yeoh, Erin J. Campbell, Morgan H. James, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 86
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials
Jodi T. Williams, Martin H. Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2337-2348
Closed Access | Times Cited: 6
Jodi T. Williams, Martin H. Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2337-2348
Closed Access | Times Cited: 6
Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
Christine Dugovic, Jonathan Shelton, Sujin Yun, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 64
Christine Dugovic, Jonathan Shelton, Sujin Yun, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 64
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57
Orexin receptor antagonists as therapeutic agents for insomnia
Ana Clementina Equihua-Benítez, Alberto K. De la Herrán-Arita, René Drucker-Colı́n
Frontiers in Pharmacology (2013) Vol. 4
Open Access | Times Cited: 57
Ana Clementina Equihua-Benítez, Alberto K. De la Herrán-Arita, René Drucker-Colı́n
Frontiers in Pharmacology (2013) Vol. 4
Open Access | Times Cited: 57
Orexin, orexin receptor antagonists and central cardiovascular control
Pascal Carrive
Frontiers in Neuroscience (2013) Vol. 7
Open Access | Times Cited: 57
Pascal Carrive
Frontiers in Neuroscience (2013) Vol. 7
Open Access | Times Cited: 57
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
Structure-based development of a subtype-selective orexin 1 receptor antagonist
Jan Hellmann, Matthäus Drabek, Jie Yin, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 18059-18067
Open Access | Times Cited: 46
Jan Hellmann, Matthäus Drabek, Jie Yin, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 30, pp. 18059-18067
Open Access | Times Cited: 46
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Expression and purification of an activated Orexin receptor 1- G-protein complex
Ioanna Ramou, Steven Janvier, Sarah Druwé, et al.
Protein Expression and Purification (2025) Vol. 228, pp. 106660-106660
Closed Access
Ioanna Ramou, Steven Janvier, Sarah Druwé, et al.
Protein Expression and Purification (2025) Vol. 228, pp. 106660-106660
Closed Access
Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer’s disease and Parkinson’s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Synthesis and Catalytic Applications of an Extended Range of Tethered Ruthenium(II)/η6-Arene/Diamine Complexes
Roy Hodgkinson, Václav Jurčı́k, Antonio Zanotti‐Gerosa, et al.
Organometallics (2014) Vol. 33, Iss. 19, pp. 5517-5524
Open Access | Times Cited: 47
Roy Hodgkinson, Václav Jurčı́k, Antonio Zanotti‐Gerosa, et al.
Organometallics (2014) Vol. 33, Iss. 19, pp. 5517-5524
Open Access | Times Cited: 47
